Unicycive Therapeutics FY2025 net loss $26.6M ($1.67/sh); OLC PDUFA date June 29, 2026

Unicycive Therapeutics, Inc.

Net loss attributable to common holders: $26.6M ($1.67/sh) vs $37.8M ($5.65/sh) in FY2024.
Cash, equivalents, securities $54.9M as of March 30, 2026; runway into 2027.
FDA accepted OLC NDA resubmission; PDUFA target action date June 29, 2026.
R&D expenses $9.1M (down from $20.0M); G&A $20.4M (up from $12.1M) due to commercial prep.
Commercial readiness for potential OLC launch in 3Q26 ongoing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Unicycive Therapeutics, Inc. reported the full year ended December 31, 2025 results: net income $26.6 million, EPS $1.67 per share of common stock.

Period: the full year ended December 31, 2025
Net income: $26.6 million
EPS: $1.67 per share of common stock
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024.

View on SEC.gov

1350 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-035961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.